Veru Inc. Announces Steven B. Heymsfield as Principal Investigator for Enobosarm Phase 2b Clinical Trial for High-Quality Weight Loss
MIAMI, FL, May 15, 2024 - Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company dedicated to developing innovative medicines for high-quality weight loss, oncology, and viral-induced acute respiratory distress syndrome, has announced the appointment of Steven B. Heymsfield, M.D. as the Principal Investigator for the Phase 2b clinical trial of enobosarm. This trial aims to preserve muscle while augmenting fat loss in patients receiving a GLP-1 RA (glucagon-like peptide-1 receptor agonist) for weight loss.
Dr. Heymsfield is a renowned expert in the field, currently serving as a Professor and the Director of the Body Composition-Metabolism Laboratory at the Pennington Biomedical Research Center in Baton Rouge, Louisiana. His vast experience in body composition and metabolism research makes him a valuable asset to Veru Inc.’s pursuit of developing effective solutions for weight loss.
The development of enobosarm in combination with GLP-1 drugs holds promising potential in achieving higher quality weight loss results than previously observed with GLP-1 drugs alone. The FDA’s recent clearance of the Investigational New Drug (IND) application for enobosarm to treat muscle loss associated with weight loss drugs is a significant milestone in the advancement of this combination therapy.
Veru Inc. submitted the IND application to the U.S. Food and Drug Administration earlier this year in January, with the goal of developing enobosarm for obesity. By preventing muscle loss and augmenting fat loss, this medication could provide a holistic approach to weight management and potentially revolutionize the treatment of obesity.
Enobosarm’s Phase 2b clinical trial aims to build upon the encouraging results observed in previous studies with GLP-1 drugs. The addition of enobosarm is expected to further enhance muscle preservation, leading to more sustainable and aesthetically pleasing weight loss outcomes.
The trial will evaluate the safety and efficacy of enobosarm when used in conjunction with GLP-1 drugs. By preserving muscle mass, patients may not only achieve their weight loss goals but also improve their overall body composition and metabolic health.
Veru Inc. is committed to developing novel medicines that address complex health challenges, such as obesity, oncology, and viral-induced acute respiratory distress syndrome. The company’s dedication to innovation and collaboration with esteemed experts like Dr. Heymsfield positions them at the forefront of advancing medical solutions for weight loss and related conditions.
In conclusion, the appointment of Dr. Steven B. Heymsfield as the Principal Investigator for Veru Inc.’s Phase 2b clinical trial for enobosarm marks a significant milestone in the company’s pursuit of high-quality weight loss solutions. With the FDA’s clearance of the IND application and the potential for enobosarm to revolutionize the treatment of obesity, Veru Inc. is well-positioned to make a positive impact on the lives of millions struggling with weight management.
This article is for informational purposes only and does not constitute medical advice. Please consult with a qualified healthcare professional for more information on enobosarm and its potential uses.’
Comments